Disease · EFO_0001072
memory impairment
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. memory impairment. Diseases, record EFO_0001072. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0001072
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs19
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| DONEPEZIL | CHEMBL502 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PHENYTOIN | CHEMBL16 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RIVASTIGMINE | CHEMBL636 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ATOMOXETINE | CHEMBL641 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CANNABINOL | CHEMBL74415 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| INSULIN HUMAN | CHEMBL1201631 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LEVETIRACETAM | CHEMBL1286 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TRICAPRILIN | CHEMBL1406148 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TROFINETIDE | CHEMBL197084 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| VILAZODONE | CHEMBL439849 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 19
See all 19 drugsTargets40
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ACHE | Acetylcholinesterase | 2 | Acetylcholinesterase inhibitor; Cholinesterases; ACHE & BCHE inhibitor | Phase 3 | https://conductscience.org/library/genes/43 | Drugs and targets |
| ADRA2A | Adrenergic receptor alpha-2 | 1 | Adrenergic receptor alpha-2 agonist | Phase 1 | https://conductscience.org/library/genes/150 | Drugs and targets |
| ADRA2B | Adrenergic receptor alpha-2 | 1 | Adrenergic receptor alpha-2 agonist | Phase 1 | https://conductscience.org/library/genes/151 | Drugs and targets |
| ADRA2C | Adrenergic receptor alpha-2 | 1 | Adrenergic receptor alpha-2 agonist | Phase 1 | https://conductscience.org/library/genes/152 | Drugs and targets |
| BCHE | Cholinesterases; ACHE & BCHE | 1 | Cholinesterases; ACHE & BCHE inhibitor | Phase 3 | https://conductscience.org/library/genes/590 | Drugs and targets |
| CACNA1B | Voltage-dependent N-type calcium channel subunit alpha-1B | 1 | Voltage-gated N-type calcium channel alpha-1B subunit blocker | Phase 2 | https://conductscience.org/library/genes/774 | Drugs and targets |
| CNR1 | Cannabinoid receptor 1 | 1 | Cannabinoid CB1 receptor agonist | Phase 1/2 | https://conductscience.org/library/genes/1268 | Drugs and targets |
| GABRA1 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive allosteric modulator | Phase 1 | https://conductscience.org/library/genes/2554 | Drugs and targets |
| GABRA2 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive allosteric modulator | Phase 1 | https://conductscience.org/library/genes/2555 | Drugs and targets |
| GABRA3 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive allosteric modulator | Phase 1 | https://conductscience.org/library/genes/2556 | Drugs and targets |
1 to 10 of 40
See all 40 targetsTrials15
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02822573 | Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil | Phase 3 | 276 | 2023-09-13 | Cognitive Dysfunction, Memory Impairment | DONEPEZIL | Its record names the disease | ClinicalTrials.gov |
| NCT01670526 | Rivastigmine Patch in Veterans With Cognitive Impairment Following TBI | Phase 3 | 94 | 2017-07-25 | Traumatic Brain Injury, Cognitive Impairment | RIVASTIGMINE | Its record names the disease | ClinicalTrials.gov |
| NCT04062123 | Memory & Conditioning Under Anesthesia | Phase 1 | 92 | 2025-04-18 | Anesthesia, Pain | DEXMEDETOMIDINE, FENTANYL, PROPOFOL | Its record names the disease | ClinicalTrials.gov |
| NCT01502813 | Citicoline, Creatine, and Omega-3 Effects in Middle Age Women | Not applicable | 40 | 2021-04-22 | Cognitive Benefits | CITICOLINE, CREATINE, OMEGA-3 FATTY ACIDS | Its record names the disease | ClinicalTrials.gov |
| NCT01828515 | Vilazodone for Corticosteroid-Induced Memory Impairment | Phase 2 | 24 | 2018-07-05 | Memory Impairment | VILAZODONE | Its record names the disease | ClinicalTrials.gov |
| NCT00591006 | Phenytoin as a Neuroprotective Agent Against Corticosteroid-induced Functional Imaging Changes | Phase 3 | 17 | 2015-08-19 | Healthy | PHENYTOIN | Its record names the disease | ClinicalTrials.gov |
| NCT03091400 | Recall Enhancement Through Treatment With Atomoxetine in MS (RETAIN-MS) | Phase 2 | 11 | 2020-03-13 | Memory Disorders, Multiple Sclerosis | ATOMOXETINE | Its record names the disease | ClinicalTrials.gov |
| NCT00355550 | Tricaprilin In Age-Associated Memory Impairment | Phase 2 | 156 | Age-Associated Memory Impairment | TRICAPRILIN | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT01766180 | Cerebrovascular and Cognitive Improvement by Resveratrol (resVida) and Fruitflow-II (CCIRF-II) | Not applicable | 80 | Memory Impairment | RESVERATROL | Its record names the disease | ClinicalTrials.gov | |
| NCT00708994 | Cannabinoids, Neural Synchrony, and Information Processing | Early phase 1 | 42 | Cannabis, Psychotic Disorders | DRONABINOL | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 15
See all 15 trialsComparisons in its trials9
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Donepezil vs Placebo: deaths from any cause | 0 of 140 | 0 of 136 | 276 | NCT02822573 | Trial comparisons |
| Donepezil vs Placebo: serious adverse events | 12 of 140 | 8 of 136 | 276 | NCT02822573 | Trial comparisons |
| Rivastigmine vs Placebo: Number of Participants With Demonstrated Improvement From Baseline on the Hopkins Verbal Learning Test-Revised (HVLT-R) Total Recall | 20 of 49 | 23 of 45 | 94 | NCT01670526 | Trial comparisons |
| Rivastigmine vs Placebo: deaths from any cause | 0 of 49 | 0 of 45 | 94 | NCT01670526 | Trial comparisons |
| Rivastigmine vs Placebo: serious adverse events | 4 of 49 | 4 of 45 | 94 | NCT01670526 | Trial comparisons |
| Vilazodone and Hydrocortisone vs Placebo and Hydrocortisone: deaths from any cause | 0 of 24 | 0 of 24 | 48 | NCT01828515 | Trial comparisons |
| Vilazodone and Hydrocortisone vs Placebo and Hydrocortisone: serious adverse events | 0 of 24 | 0 of 24 | 48 | NCT01828515 | Trial comparisons |
| Atomoxetine vs Placebo: deaths from any cause | 0 of 10 | 0 of 10 | 20 | NCT03091400 | Trial comparisons |
| Atomoxetine vs Placebo: serious adverse events | 0 of 10 | 0 of 10 | 20 | NCT03091400 | Trial comparisons |
Papers from its trials5
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0001072
GET https://conductscience.org/api/diseases/v1/EFO_0001072/targets?page=2